CLAIMS

1. Use of a bacterial secretome of a non–pathogenic Gram–negative bacterium belonging to the class Betaproteobacteria, subfamily Neisseriaceae, containing a 16S rRNA comprising sequence SEQ ID No. 1, or any sequence having at least 90% identity with sequence SEQ ID No. 1, wherein the bacterium is the bacterium deposited with the CNCM on 8 April 2010 under number I–4920, in the manufacture of a medicament, for the treatment of skin lesions,
said secretome being obtained by a process comprising the steps of:
– a) culturing said bacterium in a culture medium and under conditions suitable for its growth,
– b) liquid/solid separation and recovery of the liquid phase,
– c) obtaining said secretome comprising the biomolecules secreted by said bacterium in the liquid phase;
characterized in that a basic buffer is added to the liquid phase obtained in said step b) and that the buffered liquid phase obtained is optionally left in contact for 1 to 7 h, preferably at a temperature between 1 and 6°C, and
characterized in that the said basic buffer is selected from Tris buffer, arginine buffer and mixtures thereof.

2. The use according to claim 1, characterized in that step b) of liquid/solid separation is followed by a step b') of clarification of the liquid phase or of the buffered liquid phase by filtration before step c).

3. The use according to claim 2, characterized in that filtration is performed with a 0.2 µm cut–off.

4. The use according to one of claims 1 to 3, characterized in that said biomolecules consist of the peptides, proteins and secondary metabolites secreted by said bacterium.

5. The use according to one of claims 1 to 4, characterized in that the bacterium contains at least one plasmid comprising sequence SEQ ID No. 2, or any sequence having at least 90% identity with sequence SEQ ID No. 2.

6. The use according to one of claims 1 to 5, characterized in that the skin lesions are selected from the group consisting of abrasions, burns, sunburns, scratches, cuts, scrapes, stitches.

7. The use according to one of claims 1 to 6, characterized in that the skin lesions follow trauma, surgery, a dermatological procedure, or a cosmetic medicine procedure.

~~8. The use according to one of claims 1 to 7, characterized in that the treatment of skin lesions consists in improving healing and skin repair.~~

~~9.~~8. The use according to one of claims 1 to ~~8~~7, characterized in that ~~it~~ the bacterial secretome is combined with a copper salt and/or a zinc salt.

~~10.~~9. Use of a dermatological composition containing a bacterial secretome as defined in one of claims 1 to 5 and a dermatological excipient suitable for topical application, in the manufacture of a medicament, for the treatment of skin lesions.

~~11.~~10. Use of a dermatological composition containing a bacterial secretome as defined in one of claims 1 to 5, a copper salt and/or a zinc salt and a suitable dermatological excipient, in the manufacture of a medicament, for the treatment of skin lesions.

~~12. Use of a dermatological composition as defined in claim 11, in the manufacture of a medicament, for the treatment of skin lesions.~~